Literature DB >> 6698577

Purification of the fourth, second and fifth components of mouse complement.

Y Fukuoka, J Seino, T Okuda, T Tachibana.   

Abstract

The fourth, second and fifth components of mouse complement were purified by a combination of polyethylene glycol precipitation, ion exchange chromatography and gel filtration. The final products were homogeneous on SDS-PAGE, and the activity yields were 8.5% for C4, 32% for C2 and 40% for C5. C4 was composed of three polypeptide chains with mol. wts of 90,000, 78,000 and 32,000. C2 was composed of a single polypeptide chain with a mol. wt. of 115,000 and cleaved by C1s into two fragments with mol. wts of 80,000 and 35,000. The half life of C4b2a was 7 min and was not prolonged by the iodination of C2. C2 activity could not be measured using EAC14hu or EAC14gp cells, but measurement was possible with the use of EAC14mo cells with purified C5 components of mouse complement. C5 was composed of two polypeptide chains with mol. wts of 135,000 and 84,000. This is the first report on the purification of functionally active mouse complement components C4, C2 and C5 from plasma.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6698577      PMCID: PMC1454464     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  18 in total

1.  A SEROLOGICALLY DETECTED VARIANT IN MOUSE SERUM: FURTHER EVIDENCE FOR GENETIC CONTROL BY THE HISTOCOMPATIBILITY-2 LOCUS.

Authors:  D C SHREFFLER
Journal:  Genetics       Date:  1964-06       Impact factor: 4.562

2.  Glycoprotein staining following electrophoresis on acrylamide gels.

Authors:  R M Zacharius; T E Zell; J H Morrison; J J Woodlock
Journal:  Anal Biochem       Date:  1969-07       Impact factor: 3.365

3.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  K Weber; M Osborn
Journal:  J Biol Chem       Date:  1969-08-25       Impact factor: 5.157

4.  Variance in the activity of the fourth component of mouse complement.

Authors:  Y Fukuoka; T Okuda; T Tachibana
Journal:  Tohoku J Exp Med       Date:  1983-10       Impact factor: 1.848

5.  Complement-independent activation of the fifth component (C5) of human complement: limited trypsin digestion resulting in the expression of biological activity.

Authors:  R A Wetsel; W P Kolb
Journal:  J Immunol       Date:  1982-05       Impact factor: 5.422

6.  The reaction mechanism of human C5 in immune hemolysis.

Authors:  N R Cooper; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1970-10-01       Impact factor: 14.307

7.  Purification and structural analysis of the fourth component of human complement.

Authors:  C Bolotin; S Morris; B Tack; J Prahl
Journal:  Biochemistry       Date:  1977-05-03       Impact factor: 3.162

8.  The purification and properties of the second component of guinea-pig complement.

Authors:  M A Kerr; J Gagnon
Journal:  Biochem J       Date:  1982-07-01       Impact factor: 3.857

9.  Enharncement of the hemolytic activity of the second component of human complement by oxidation.

Authors:  M J Polley; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1967-12-01       Impact factor: 14.307

10.  Fifth component of guinea pig complement: purification and characterization.

Authors:  T Kinoshita; K Hong; K Kondo; K Inoue
Journal:  J Immunol       Date:  1981-06       Impact factor: 5.422

View more
  3 in total

1.  Experimental lupus nephritis in severe combined immunodeficient (SCID) mice: remodelling of the glomerular lesions by bystander IgM antibodies.

Authors:  M R Ito; S Terasaki; E Kondo; H Shiwaku; Y Fukuoka; M Nose
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

2.  Structural polymorphism of mouse complement C2 detected by microscale peptide mapping: linkage to H-2.

Authors:  S Takahashi; Y Fukuoka; K Moriwaki; T Okuda; T Tachibana; S Natsuume-Sakai; M Takahashi
Journal:  Immunogenetics       Date:  1984       Impact factor: 2.846

3.  Recombinant human complement component C2 produced in a human cell line restores the classical complement pathway activity in-vitro: an alternative treatment for C2 deficiency diseases.

Authors:  Paolo G V Martini; Lynette C Cook; Scott Alderucci; Angela W Norton; Dianna M Lundberg; Susan M Fish; Knut Langsetmo; Göran Jönsson; Christian Lood; Birgitta Gullstrand; Kate J Zaleski; Nancy Savioli; Jason Lottherand; Charles Bedard; John Gill; Michael F Concino; Michael W Heartlein; Lennart Truedsson; Jan L Powell; Arthur O Tzianabos
Journal:  BMC Immunol       Date:  2010-08-20       Impact factor: 3.615

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.